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ABSTRACT
The breast and ovarian cancer suppressor
protein BRCA2 controls the RAD51 recombinase in
reactions that lead to homologous DNA recombina-
tion (HDR). BRCA2 binds RAD51 via eight conserved
BRC repeat motifs of approximately 35 amino acids,
each with a varying capacity to bind RAD51. BRC
repeats both promote and inhibit RAD51 assembly
on different DNA substrates to regulate HDR, but
the structural basis for these functions is unclear.
Here, we demarcate two tetrameric clusters of
hydrophobic residues in the BRC repeats, interact-
ing with distinct pockets in RAD51, and show that
the co-location of both modules within a single
BRC repeat is necessary for BRC–RAD51 binding
and function. The two modules comprise the
sequence FxxA, known to inhibit RAD51 assembly
by blocking the oligomerization interface, and a
previously unrecognized tetramer with the con-
sensus sequence LFDE, which binds to a RAD51
pocket distinct from this interface. The LFDE
motif is essential in BRC repeats for modes of
RAD51 binding both permissive and inhibitory to
RAD51 oligomerization. Targeted insertion of point
mutations in RAD51 that disrupt the LFDE-binding
pocket impair its assembly at DNA damage sites in
living cells. Our findings suggest a model for the
modular architecture of BRC repeats that provides
fresh insight into the mechanisms regulating homol-
ogous DNA recombination.
INTRODUCTION
The BRCA2 tumour suppressor is essential for homolo-
gous DNA recombination (HDR), a process for the error-
free repair of DNA double-stranded breaks (DSBs), in the
cells of higher eukaryotes (1,2). BRCA2 orthologues exist
in most eukarya, with the notable exception of yeast (3).
Their central function during HDR (4) is to control the
RAD51 recombinase (5,6), an enzyme conserved in the
other kingdoms of life as RecA in eubacteria, or RadA
in archaea. RAD51 is indispensable for HDR (7–9),
which begins when broken DNA is end-resected to
generate ssDNA, upon which RAD51 oligomerizes to
form an active nucleoprotein ﬁlament. The RAD51
nucleoprotein ﬁlament catalyzes strand exchange by
invading and pairing with a homologous DNA duplex,
used as a template for repair. Several functions have
been ascribed to the BRCA2-RAD51 interaction, both
in vivo and in vitro, in regulating these events. They
include the sequestration of RAD51 in undamaged cells
and its mobilization after damage (10), targeting of
RAD51 to DSBs (11), control of RAD51 oligomerization
(12,13) and modulation of sequential DNA substrate
selection by RAD51, a process that orders the strand
exchange reaction itself (14,15).
Two distinct regions in human BRCA2 bind directly to
RAD51. Eight BRC repeats, evolutionarily conserved
motifs of approximately 35 residues each, distributed in
a 1100 residue region of BRCA2 (BRCA2BRC1-8), are
conserved amongst vertebrate orthologues in both their
sequence and spacing (16–18). Each of the eight BRC
repeats in human BRCA2, despite only subtle sequence
variation, exhibits a varying aﬃnity for RAD51 (19–21).
BRC repeats, in isolation, or in the context of
BRCA2BRC1-8, bind RAD51 complexes on DNA (22,23)
and diﬀerentially regulate RAD51 assembly on ssDNA
versus dsDNA, promoting loading onto ssDNA, whilst
concurrently impeding loading onto dsDNA, thereby
stimulating strand exchange (14,15). A second, distinct,
RAD51-interacting region located at the extreme
C-terminus of BRCA2 stabilizes RAD51 oligomeric
assemblies in vitro both on and oﬀ DNA (24,25).
However, recent cellular studies suggest that the
C-terminal RAD51-binding region is dispensable for
the execution of HDR in vivo, and instead, coordinates
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Thus, the binding of BRCA2’s BRC repeats to RAD51
may be the primary mode of interaction between the two
proteins relevant to HDR.
The structure of a complex between human BRC repeat
4 (BRC4) and the core catalytic domain of RAD51
provides insight into this interaction. BRC4 uses the
sequence FHTA (human BRCA2 residues 1524–1527)
within the context of a b-hairpin secondary structural
motif to directly mimic the inter-subunit oligomerization
motif of the RAD51 protein (13). In this mode of interac-
tion, the BRC4-RAD51 interaction is expected to inhibit
RAD51 oligomerization, consistent with the observations
that excess BRC repeat peptides (at >3–4:1 molar
ratios) antagonize RAD51 nucleoprotein ﬁlament forma-
tion in vitro (12) or the formation of RAD51 nuclear foci
in vivo (13,19). However, it has become clear through later
studies that a second mode of BRC–RAD51 interaction
also exists, which is permissive for RAD51 oligomeriza-
tion on DNA. At lower stoichiometries of interaction
approaching 1:1 molar ratios, BRC repeats in isolation
or in the context of the entire BRCA2BRC1-8 region, can
bind to RAD51 nucleoprotein ﬁlaments (22,23), and
promote strand exchange reactions in vitro (8,23,27).
Indeed, recent data suggest that isolated BRC repeats or
the BRCA2BRC1-8 fragment promote the stable interaction
of RAD51 with ssDNA substrates, whilst inhibiting
assembly on dsDNA, and that these opposing activities
reinforce one another to favour sequential progression
through the steps of HDR (14,15). Thus, biochemical
and cellular studies indicate that the BRC repeats
of human BRCA2 can interact with RAD51 in modes
inhibitory or permissive to RAD51 oligomerization on
DNA substrates. However, the structural basis for these
seemingly disparate interactions remains unclear.
Here, we have combined structural modelling, biochem-
istry, cell biology and genetics to address how BRC repeat
binding to RAD51 may inﬂuence function. We identify
two tetrameric motifs for RAD51 binding in the BRC
repeats, deﬁning a previously unrecognized motif, LFDE
(human BRC4 nomenclature), which is essential for the
BRC-RAD51 interaction in BRC repeats of divergent
sequence. Although both motifs are required for potent
interaction with RAD51, their engagement in structurally
discrete binding sites on RAD51, their diﬀerential
contributions to RAD51 binding by diﬀerent BRC
repeats, and their occurrence within distinct secondary
structural motifs of ﬁxed spacing, argue that these sites
may constitute distinct binding modes. Consistent with
its essential function, abrogation of the LFDE-binding
pocket in RAD51 by insertion of point mutations
triggers cellular lethality and defective RAD51 assembly
at sites of DNA damage. Indeed, we show by structural
modeling that the LFDE–RAD51 interaction conserves a
salt bridge critical for nucleoprotein ﬁlament formation by
bacterial RecA, an example of molecular mimicry during
evolution, and the second identiﬁed at the BRC4–RAD51
interface. Our ﬁndings suggest a model in which two
discrete modules are used in BRC repeats for unique
modes of binding to RAD51, which help to explain their
inhibitory and permissive functions during RAD51
oligomerization on DNA substrates. This work provides
fresh insight into the mechanism of HDR and its regula-
tion by the BRC repeats of BRCA2.
MATERIALS AND METHODS
Cloning
The mCherry-HsRAD51 expression construct, comprising
RAD51 with an N-terminal mCherry ﬂuorophore tag, was
a kind gift of Robert Mahen. Site-directed mutagenesis
was performed using the Quickchange Site-Directed
Mutagenesis Kit (Stratagene). All clones were veriﬁed
by nucleotide sequencing (Geneservice Ltd). RAD51 was
subcloned into pET28a(+), containing an N-terminal
6His tag fusion, via the NheI–BamHI sites in the
multiple cloning site.
Protein puriﬁcation
Recombinant RAD51, cleaved from GST-RAD51, was
used for enzyme-linked immunosorbent assays (ELISA).
The bacterial expression plasmid pGex2TK-HsRad51 was
a kind gift of Dr Debbie Bates. GST-RAD51 was
prepared from Escherichia coli BL21 cells using standard
aﬃnity puriﬁcation protocols with glutathione-
sepharose 4B beads (Amersham). RAD51 was cleaved
from the GST moiety by overnight incubation at 22C
with thrombin protease (Amersham), dialysed into PBS
in a Slide-A-Lyser 10000 MWCO Dialysis Cassette
(Pierce) and concentrated using a Vivaspin-15 10000
MWCO concentrator (Sartorius). Untagged RAD51
used in electrophoretic mobility shift assays (EMSA)
and recombinant biotinylated peptide pull downs was a
kind gift of Jane Savill. Untagged RAD51
R250A was
prepared using the same method described for
RAD51(23).
Peptides
All peptides were synthesized by Cambridge Research
Biochemicals Ltd or Peptide Protein Research Ltd
with an N-terminal biotin moiety attached through a
6-aminohexanoic acid spacer, and a C-terminal amide.
Peptides were puriﬁed to 95% by HPLC, sequence-
veriﬁed by time-of-ﬂight mass spectrometry and diluted
in water (supplemented with 5mM DTT if containing
cysteine residues).
DT40 transfection
All constructs were transfected into Rad51
//
HsRAD51
Tet oﬀ DT40 cells as previously described (28).
Cell viability
Independent DT40 clones were grown and maintained in
log phase. Viable cells were enumerated after trypan blue
staining using a Beckman Coulter Vicell XR Cell Viability
analyzer.
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Whole-cell extracts were prepared in ice-cold RIPA
buﬀer, resolved by by SDS–PAGE and immuno-blotted
as detailed in Supplementary Methods.
Streptavidin-bead peptide pull-down assay
Pull down of RAD51 using biotinylated BRC peptides
was performed as outlined in Supplementary Methods.
ELISA
Competitive ELISA experiments using biotinylated BRC
peptides to disrupt the BRC4–RAD51 interaction were
performed as outlined in Supplementary Methods.
Sister chromatid exchange assay
The sister chromatid exchange assay in the presence or
absence of 50ng/ml mitomycin C was performed as
described previously (29) and in the Supplementary
Methods.
Microscopy
Direct mCherry-RAD51 imaging was initially performed
on a Zeiss LSM510 Meta confocal microscope and
enumerated by automated microscopy on an Olympus
ScanR high-content screening microscope as decribed in
Supplementary Methods.
EMSA
EMSAs were performed as previously described (15,23).
Brieﬂy, RAD51 at 2mM and BRC repeats at indicated
concentrations were pre-incubated in a 10ml reaction
volume on ice for 10 minutes. Preformed complexes
were incubated with 6mM
32P-labeled ApaL1-linearised
X174 dsDNA (New England Biolabs) in buﬀer B
(40mM Tris–HCl, pH 7.8, 1mM MgCl2, 1mM DTT,
1mM AMPPNP and 200mM KCl) at 37C for a
further 60 min. The protein–DNA complexes on dsDNA
were resolved by 0.5% agarose gel electrophoresis in TAE
buﬀer at 50mA for 4 h at 4
oC. The dried gels were
exposed to a phosphorimager screen and visualized on a
FujiFilm FLA-5000 processor.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism version 5 for Windows (GraphPad Software).
Structural analysis
All structures were modeled and images prepared using
the PyMOL Molecular Graphics System (http://pymol
.org/). The numerical solution of the Poisson–Boltzmann
equation over the solvent surface of RAD51 was
generated using the Adaptive Poisson–Boltzmann Solver
(APBS) and is coloured according to the electrostatic
potential (10kT to +10kT) calculated in the absence
of BRC4 (30). Solvent accessible surface areas (SASAs)
of the RAD51 and BRC4 proteins from 1N0W were
calculated using POPSCOMP (31).
Bioinformatics analysis
Sequence alignments were generated using the ClustalW2
alignment program and processed with JalView 2.3
(32,33). Sequences are rendered with the default
ClustalX colour scheme, assigning colours to residues if
the amino acid proﬁle at the given position is conserved
by both residue type and above a minimum threshold of
percentage presence.
RESULTS
Two tetrameric clusters of hydrophobic residues in the
BRC4 repeat contact RAD51
The high-resolution crystal structure of a fusion pro-
tein containing the RecA-homology domain of RAD51
(residues E98-D339) in complex with human BRC
repeat 4 (BRC4, BRCA2 residues 1519–1551) has been
previously reported (PDB ID: 1N0W) (Figure 1A) (13).
The N-terminal domain of RAD51, as well as the linker
region connecting it to the core catalytic domain that
contains a tetrameric cluster of residues 86-FTTA-89 nec-
essary for RAD51 oligomerization, are both absent from
the crystallized RAD51-BRC4 complex. This renders the
complex monomeric, and exposes the entire interaction
surface necessary and suﬃcient for BRC4 interaction
(13,34).
Crucially, the structure shows that a region of BRC4,
1524-FHTA-1527, positioned within the context of a
b-hairpin, binds directly to the oligomerization interface
of RAD51. The FHTA motif in the BRC4 peptide
occupies two hydrophobic pockets that would, in a
RAD51 oligomer, be occupied by the FTTA motif in
RAD51 to mediate inter-subunit contact (13). Thus,
BRC4 mimics the oligomerization interface in RAD51,
suggesting a mechanism for antagonism of RAD51
oligomerization. The FHTA motif of BRC4 is represented
in other mammalian BRCA2 and RAD51 homologues as
the consensus sequence FxxA, in which the F and A side
chains are expected to make contacts with hydrophobic
pockets on the core catalytic domain of RAD51.
The C-terminal portion of BRC4 in the BRC4–RAD51
complex, comprising residues I1534-Q1551, constitutes a
distinct secondary structural domain, within an a-helical
context, that could also be important for interaction
with RAD51 (Figure 1). This region makes contacts
with RAD51 distant from the oligomerization interface,
and in full-length RAD51, would likely cause a steric clash
with the N-terminal domain, which is absent from the
crystallized complex (22,34).
To dissect the contribution of this second region in
BRC4 to the BRC4–RAD51 interaction, we compared
the surface properties of BRC4 and RAD51 in their
native and co-complexed states (31). The majority of the
SASA lost when the proteins interact is hydrophobic
(Figure 1B), a common feature in protein–protein
interactions (35,36). The eﬀect on RAD51 is less signiﬁ-
cant because the interaction with BRC4 consumes a
smaller proportion of its total surface, but an eﬀect is
still observable.
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Figure 1. Two distinct hydrophobic motifs within BRC repeats constitute the majority of interaction with RAD51. (A) Ribbon representation of the
human BRC4-RAD51 interface (PDB ID: 1N0W). The N-terminal BRC4 hairpin (residues 1519–1533) and a-helical C-terminus (residues 1534–1551)
are coloured magenta and blue, respectively. RAD51 is in green with a transparent solvent accessible surface.(B) Histogram showing the loss of
SASA that occurs between unbound and bound BRC4 peptide (grey) on interaction with the core domain of RAD51 and the equivalent eﬀect on
RAD51 (black). 25.4% of total SASA on BRC4 is lost of which 30.4% is hydrophobic and only 15.7% is hydrophilic. (C) Histogram showing the
contribution of each residue in BRC4 to interaction with Rad51, as measured by buried surface area on binding to RAD51. Two BRC4 motifs,
FHTA (residues 1524–1527) and LFDE (1545–1548), consist of residues contributing strongly to buried surface area and are clustered around the
two most buried residues, F1524 and F1546, that constitute 16.3% and 11.4% of total buried area. (D) Sequence alignment of all eight human BRC
repeats and the single BRC repeat found in Caenorhabditis elegans Brc-2 and Ustilago maydis Brh2. Both the FHTA and LFDE motifs are strongly
conserved by amino acid similarity and spacing in BRC1-8 and the hydrophobic component of the LFDE motif across all BRC repeats.
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RAD51 cluster into two predominantly hydrophobic
motifs, each of four residues, which comprise the
majority of buried surface area at the RAD51–BRC4 inter-
face (Figure 1C). The ﬁrst tetrameric cluster has the
sequence FHTA (residues 1524–1527); the molecular
mimic of the native RAD51 oligomerization sequence 86-
FTTA-89. However, a second motif, LFDE (residues
1545–1548), resides in the C-terminus of the BRC4 peptide.
The LFDE motif is conserved in all eight human BRC
repeats, with hydrophobic residues in the ﬁrst and second
positions, and either an acidic residue (BRC1, BRC2,
BRC4, BRC5–BRC8) or glutamine (BRC3) in the fourth
position (Figure 1D). The third position of the tetramer is
redundant, in keeping with this residue being solvent-
exposed (Figure 1A). Intriguingly, the two initiating
hydrophobic residues of the LFDE motif in particular,
are conserved not just in all eight human BRC repeats,
but even in a BRCA2 orthologue from a simple eukaryote
which possesses but a single BRC-repeat (Figure 1D) (3).
In comparison, the FHTA tetramer is conserved in seven
repeats (but not BRC5) as FxxA, with a threonine residue
found at the third position in six of the eight repeats
(excepting BRC2 and BRC6), as well as in the FTTA
motif native to RAD51.
Both tetrameric clusters are necessary for the
BRC–RAD51 interaction
To test whether the BRC4-RAD51 interaction relies on
both tetrameric clusters, we developed an ELISA assay,
which measured the ability of wild-type or mutant BRC
peptides (Table 1) to compete for the interaction between
BRC4 peptide (in the solid phase) and recombinant
full-length RAD51 (in solution) (Figure 2A). Mutant
BRC peptides contained either an F1524E mutation
(recapitulating a substitution in the FxxA cluster shown
to disrupt RAD51 oligomerization (10)) or the combined
substitution of the hydrophobic residues in the LFDE
cluster with glutamic acid, and the terminal charged
residue with alanine (i.e. L1545E, F1546E, E1548A). For
downstream assays, peptides were N-terminally
biotinylated; this moiety had no eﬀect on BRC repeat
functionality in direct comparison with unconjugated
peptides either as a soluble inhibitor or for solid-phase
capture of RAD51 (Supplementary Figure S1).
Our ﬁndings suggest that the FHTA and LFDE inter-
action motifs in BRC4 are together necessary for the
BRC4–RAD51 interaction. Thus, mutant peptides
containing substitutions disrupting the two motifs indi-
vidually or in combination failed to competitively
inhibit the BRC4–RAD51 interaction in the ELISA
assay (Figure 2B).
Conversely, conservative substitution with tryptophan
of the phenylalanine residues F1524 andF1546, which con-
tribute the majority of buried surface area to interaction
with RAD51 (i.e. F1524W and F1546W (Figure 1C)) does
not greatly alter the ability of mutant peptides to
competitively inhibit the BRC4–RAD51 interaction
(Figure 2B). Although the indole moiety of tryptophan is
larger than the benzyl group in phenylalanine, structural
modelling predicts that it can still be accommodated in
both the FHTA- and LFDE-binding pockets of RAD51
(Figure 2C and D, respectively). Moreover, BRC4-derived
peptides harbouring single F1524W and F1546W
substitutions combined with mutations disrupting the
remaining tetrameric motif (i.e. BRC4
WE and BRC4
EW,
respectively) fail to competitively inhibit the BRC4–
RAD51 interaction. Thus collectively, our results indicate
that both the FHTA and LFDE motifs in BRC4 are nec-
essary for interaction with RAD51. These motifs bind to
distinct pockets in RAD51, which can be considered inter-
action hotspots at which the majority of buried surface
areaisfoundatresiduesF1524andF1546inBRC4(37,38).
A chimaeric fusion between BRC4 and BRC5 functionally
reconstitutes a potent BRC repeat
An intriguing feature is that each of the human BRC
repeats has a varying aﬃnity for RAD51. Most notably,
the BRC5 repeat has been shown to have the lowest
aﬃnity, in contrast to BRC4 (20,21,39). Despite this,
Table 1. BRC-derived peptides used in this study
Name Sequence FxxA LFDE
BRC4 KEPTLLGFHTASGKKVKIAKESLDKVKNLFDEKEQ intact intact
BRC4
EF KEPTLLGEHTASGKKVKIAKESLDKVKNLFDEKEQ mutated intact
BRC4
FE KEPTLLGFHTASGKKVKIAKESLDKVKNEEDAKEQ intact mutated
BRC4
EE KEPTLLGEHTASGKKVKIAKESLDKVKNEEDAKEQ mutated mutated
BRC4
EW KEPTLLGEHTASGKKVKIAKESLDKVKNLWDEKEQ mutated F to W
BRC4
WE KEPTLLGWHTASGKKVKIAKESLDKVKNEEDAKEQ F to W mutated
BRC4
WW KEPTLLGWHTASGKKVKIAKESLDKVKNLWDEKEQ F to W F to W
BRC4
E1548A KEPTLLGFHTASGKKVKIAKESLDKVKNLFDAKEQ intact E1548A
BRC5 IENSALAFYTSCSRKTSVSQTSLLEAKKWLREGIF intact intact
BRC
45 KEPTLLGFHTASGKKVKVSQTSLLEAKKWLREGIF BRC4 BRC5
BRC
54 IENSALAFYTSCSRKTSIAKESLDKVKNLFDEKEQ BRC5 BRC4
BRC
4A KEPTLLGFHTASGKKVK FHTA (BRC4)
BRC
5A IENSALAFYTSCSRKTS FYTS (BRC5)
BRC
4B IAKESLDKVKNLFDEKEQ LFDE (BRC4)
BRC
5B VSQTSLLEAKKWLREGIF WLRE (BRC5)
All peptides are N-terminal biotinylated and are based on the core 35 amino acid register of BRC4
86 Nucleic AcidsResearch, 2010,Vol. 38,No. 1BRC5 contains the LFDE-like motif 1692-WLRE-1695.
This might conceivably confer stronger binding than the
native LFDE sequence in BRC4, since the substitution
could contribute more buried surface area into the large
hydrophobic pocket in RAD51. The native BRC5
tetrameric cluster WLRE has two hydrophobic residues
in the ﬁrst and second positions and a glutamate in the
fourth. We reasoned that residues W1692 and L1693 in
the BRC5 peptide could also be accommodated in the
same pocket used by BRC4 residues L1545 and F1546.
W1692 is in the ﬁrst position in the BRC5 tetrameric
cluster but F1546, which can be functionally reconstituted
by a tryptophan (Figure 2B and D), is in the second
position of the LFDE cluster in BRC4 (Figure 1D).
To test this hypothesis, we ﬁrst synthesized peptides
spanning residues 1–17 and 18–35 from the 35-residue
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electrostatic clash, to tryptophan (orange, stick). The indole side chains of tryptophan adopt a similar binding pose to the benzyl side chains of the
phenylalanines.
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shown in Figure 1D. The 17-mer N-terminal BRC4
peptide BRC
4A (containing the 1524-FHTA-1527 motif)
was able to compete with a modest potency against
full-length BRC4 for RAD51 binding (Figure 3A), as
did the 18-mer BRC4 or BRC5 C-terminal peptides
BRC
4B (containing 1545-LFDE-1548) and BRC
5B (con-
taining 1692-WLRE-1695). However, the N-terminal
peptide BRC
5A (containing 1671-FYTS-1674) did not
exhibit signiﬁcant inhibition. This may be explained by
the replacement of alanine in the FHTA motif of BRC4,
a small non-polar residue which is partially buried in
RAD51, with a polar serine residue in the FYTS motif
in BRC5.
To further explore the contribution made by the two
tetrameric clusters to RAD51 binding, we constructed
chimaeric peptides in which the N- or C-terminal
segments from BRC4 and BRC5 were combined. Thus,
peptide BRC
45 combines the N-terminal 17 residues
from BRC4 (containing 1524-FHTA-1527) with the
C-terminal 18 residues from BRC5 (containing 1692-
WLRE-1695), whereas BRC
54 combines the converse
segments, joining the 1671-FYTS-1674 motif from
BRC5 with the 1545-LFDE-1548 from BRC4 in a
35-mer peptide. We tested whether functional FHTA
and LFDE motifs in a BRC repeat are together necessary
for the BRC-RAD51 interaction, because mutations that
individually disrupt the FHTA or LFDE motifs in BRC4,
or the natural alanine–serine substitution in the FxxA
motif in BRC5, can abrogate their interaction with
RAD51. Indeed, a chimaeric fusion peptide containing
the N-terminus of BRC4 and C-terminus of BRC5
(BRC
45) phenocopied BRC4 in its behaviour as a
soluble inhibitor of the BRC4–RAD51 interaction
(Figure 3B). In contrast, the BRC
54 fusion, combining
the N-terminus of BRC5 with the C-terminus of BRC4,
had little competitive eﬀect, and resembled the BRC5
peptide in its behaviour. Interestingly, as predicted from
the enhanced inhibitory potential of BRC
5B over BRC
4B
(Figure 3A), the BRC
45 fusion, containing the FHTA
motif of BRC4 and the WLRE motif in BRC5, was
more potent than BRC4 at competing the BRC4–
RAD51 interaction.
The ability of wild-type, mutant or chimaeric BRC
repeat peptides to compete with BRC4 for binding to
RAD51 in the ELISA assay was further validated by mea-
suring their interaction with RAD51. Biotinylated BRC
peptides bound to streptavidin-coated magnetic beads
were used to pull down endogenous RAD51 from
human 293T cell lysates (Figure 4). After stringent
washes of the bead-bound protein complexes, samples
were analysed by SDS–PAGE and western blotting for
RAD51. As expected, the BRC4 wild-type peptide, the
tryptophan-substituted BRC4
WW mutant, or the BRC
45
chimera, all containing both the FHTA and LFDE
motifs, eﬃciently pulled-down RAD51 from lysates
(Figure 4A and B). The BRC5 wild-type peptide
interacted only weakly with RAD51, as did the C-
terminal 18-mer peptide BRC
5B (Figure 4C). However,
neither the 17/18-mer BRC
4A nor BRC
4B peptides could
pull down RAD51 from cell lysates, in agreement with a
previous report (40), despite possessing the ability to
compete for the BRC4–RAD51 interaction in the
ELISA assay. These latter observations suggest that the
C-terminal region of the BRC5 repeat, encoded in BRC
5B,
may bind more strongly to RAD51 than the equivalent
region of the BRC4 repeat, encoded in BRC
4B. This is
surprising, because full-length BRC4 is a much stronger
binder of RAD51. The failure to detect a direct interaction
with the BRC
4A peptide, which showed competitive
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Figure 3. A chimaeric fusion peptide of the N-terminus of BRC4 and
C-terminus of BRC5 reconstitutes a functional BRC4-like peptide.
(A) The inhibitory potential of isolated N- and C-terminal peptides
from BRC4 and BRC5: BRC
4A, BRC
4B, BRC
5A and BRC
5B (see
Table 1 for sequence). BRC
4A and BRC
4B alone have inhibitory poten-
tial (although a signiﬁcantly lower potency than full length BRC4, see
Figures 2B and 3B for comparison). The BRC
5B peptide, containing the
C-terminus of BRC5, but not BRC
5A, has inhibitory potential also. (B)
A peptide containing a fusion of the N-terminal FHTA motif of BRC4
and the C-terminal WLRE motif of BRC5 acts as a potent soluble
inhibitor of the BRC4–RAD51 interaction. Peptides corresponding to
BRC5 and an inverse fusion of the N-terminus of BRC5 and the C-
terminus of BRC4 fail to show signiﬁcant inhibitory behaviour.
88 Nucleic AcidsResearch, 2010,Vol. 38,No. 1inhibition in the ELISA, may reﬂect diﬀerences in its
ability to form a stable hairpin structure in solution (i.e.
in the ELISA) or when tethered on beads (i.e. in the pull-
down assay).
Collectively, these results indicate that the BRC
repeats use two distinct tetrameric clusters of residues
in distinct secondary structural domains (in BRC4,
a N-terminal b-hairpin containing FHTA, and a
C-terminal a-helix containing LFDE) to bind to two
separate pockets in RAD51. These tetrameric clusters
jointly contribute to the ability of BRC repeats to bind
RAD51. Thus, BRC4, which exhibits potent binding
to RAD51, contains N- as well as C-terminal motifs
that contribute to the interaction (40). In contrast, the
N-terminal tetrameric motif in BRC5 may be incapable
of binding to its cognate pocket in RAD51, which may
account for the relatively weak aﬃnity of this repeat
for RAD51.
Co-location of FxxA and LFDE motifs within a single
BRC repeat allows inhibitory and permissive modes
of RAD51 regulation
To understand the functional signiﬁcance of two distinct
binding sites for RAD51 within a single BRC repeat, we
compared the behaviour of mutant and chimaeric BRC
repeats in an EMSA. RAD51 forms a nucleoprotein
complex with a radiolabeled linear dsDNA substrate at
an optimal base pair to RAD51 ratio of 3:1 (41). As
expected, this ﬁlament is super-shifted by the addition of
BRC4 at a low concentration ranging up to a 2:1 molar
ratio with RAD51, reﬂecting the formation of a ternary
complex (12,23). In contrast, ternary complex formation is
inhibited at a high BRC4 concentration, greater than a
2:1 molar ratio with RAD51. Together, these behaviours
reﬂect two functional states, in which BRC repeats are
either permissive or inhibitory for RAD51 assembly on
dsDNA (12,22).
Mutations in the BRC repeats perturb these functional
behaviours. Point mutants that inactivate the FHTA or
LFDE motifs, singly or in combination, fail to form a
ternary complex with RAD51 and dsDNA in the EMSA
at lower concentrations, and do not inhibit complex for-
mation at higher concentrations (Figure 5A). This
suggests that the FHTA and LFDE motifs are both
required for the permissive or inhibitory interactions of
BRC repeats with a RAD51-dsDNA ﬁlament. Indeed,
neither the BRC5 peptide (which lacks a functional
FxxA motif near its N-terminus) nor the chimaeric
peptide BRC
54 (in which the N-terminal sequence of
BRC5 is fused with the C-terminal region of BRC4)
exhibit either functional behaviour in the EMSA.
Interestingly and in contrast, the chimeric BRC
45 fusion
peptide (which contains functional versions of the N- and
C-terminal motifs) exhibits both behaviours. It forms
ternary complexes with RAD51-dsDNA at up to a
molar ratio of 2:1, and inhibits complex formation
when present in higher amounts (Figure 5B) thus display-
ing similar stoichiometric eﬀects to BRC4. Thus, we ﬁnd
that the co-location of the FxxA and LFDE motifs within
a single BRC repeat is necessary for permissive and inhib-
itory eﬀects on ternary complex formation with RAD51
and dsDNA. Since the binding site on RAD51 for the
FxxA motif perturbs the interface for RAD51
oligomerization, whereas the LFDE-binding site is
distant from it, this raises the possibility that the two
motifs represent distinct binding modes adopted by the
BRC repeats to regulate RAD51 in a manner inhibitory
(FxxA) or permissive (LFDE) to its oligomerization.
The binding site on RAD51 for the LFDE motif is
critical for in vivo function
To test the biological function of the LFDE motif, we
used avian DT40 cells, a widely used model for the
study of HDR (42). The BRC repeats of chicken Brca2
display homology with other known vertebrate BRC
repeats in number, inter-repeat spacing and critical
sequence ﬁngerprints, including both the FxxA and
LFDE modules (3). Chicken BRC3 and BRC5 deviate
somewhat from their corresponding human counterparts,
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Figure 4. Presence of both binding motifs within a BRC repeat is
required for strong interaction with RAD51. (A) A western blot of
RAD51 pulled down from 293T whole-cell extract using BRC4-
derived biotinylated peptides with streptavidin-coated magnetic beads.
Concurring with data in Figure 2B, only a peptide containing an intact
FHTA and LFDE, or combined F1524W and F1546W mutation, could
directly interact with RAD51. No non-speciﬁc binding occurs to
streptavidin-coated magnetic beads or addition of unconjugated
BRC4 peptide. (B) is as in (A) and indicates very weak interaction
between BRC5 and Rad51, but strong interaction with chimaeric
peptide BRC
45.( C) is as in (A) and demonstrates that BRC
5B is the
only truncated BRC peptide capable of interaction with Rad51,
although only visible at an extended exposure of the blot.
Nucleic AcidsResearch, 2010,Vol. 38,No. 1 89the former lacking identiﬁable FxxA and LFDE motifs,
and the latter, containing an SLPV motif that diverges
signiﬁcantly from FxxA (3). Avian Rad51 is closely
homologous to its human counterpart, and can be func-
tionally replaced by wild-type human RAD51 (28), but
not mutants that fail to bind chicken BRC repeats (10),
suggesting functional conservation of the in vivo interac-
tion between these proteins.
We deﬁned the RAD51 residues that mediate its binding
to the LFDE motif, before creating RAD51 mutants
bearing alterations in these residues, to overcome tech-
nical challenges of introducing LFDE mutations in each
of the eight BRC repeats of chicken Brca2. We designed
mutations disrupting both polar and non-polar interac-
tions predicted to be critical from the BRC4–RAD51
structure (3,13). Mutation R250A abrogates a putative
critical salt bridge to E1548 in human BRC4, the acidic
residue in the fourth position of the LFDE-motif,
conserved in seven of the eight human BRC repeats
(Figure 6, left panel). The two initiating hydrophobic
residues in the LFDE motif (L1545 and F1546) occupy
a pocket in RAD51 with the potential to be occupied by
two hydrophobic residues found in conserved positions in
all eight human repeats. Two conserved leucine residues,
L204 and L255, within 5A ˚ of the ‘L1545/F1546’ motif at
the base of the pocket are predicted to signiﬁcantly con-
tribute to its hydrophobicity (Figure 6, right panel).
In silico mutagenesis of these two residues to glutamate
predicts that the introduction of bulk and charge will
alter the required topology and electrostatic potential
(Supplementary Figure S2) for occupation by the two
hydrophobic residues in the LFDE motif of BRC repeats.
We introduced these mutations into human RAD51
expressed in DT40 cells in which endogenous Rad51
has been deleted by gene targeting (28). It has previously
been shown that wild-type human RAD51, or a GFP-
ﬂuorophore tagged form, can functionally replace endo-
genous Rad51 in these cells, providing a robust model
 BRC4
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Figure 6. In silico mutagenesis of HsRAD51 identiﬁes polar and non-
polar residues required for interaction with the LFDE motif of BRC4.
A ribbon representation of BRC4 (cyan) and RAD51 (green) at the
LFDE interaction site is shown. Polar contacts in the left panel indicate
salt bridges between R250 in RAD51 and E1548 in BRC4 and between
R247 in RAD51 and the backbone of F1546 in BRC4. The right panel
identiﬁes L204 and L255 as two hydrophobic residues at the base of the
LFDE binding pocket in RAD51. All residues in stick representation
are within 5A ˚ of L1545 and F1546 in BRC4.
90 Nucleic AcidsResearch, 2010,Vol. 38,No. 1widely used for the genetic analysis of RAD51 function
(10). Because RAD51 is essential for cell viability,
Rad51
/ DT40 cells were stably complemented with
a conditional, Tet-repressible construct encoding wild-
type human RAD51 (HsRAD51
Tet oﬀ), as well as with
constructs encoding wild-type or mutant forms of
mCherry-tagged RAD51. The addition of doxycycline
eliminates HsRAD51
Tet oﬀ expression, leaving only the
doxycycline-resistant mCherry-tagged forms (genotypes
indicated in Figure 7A). mCherry-RAD51
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B
C
D
c
l
o
n
e
 
1
8
R
A
D
5
1
W
T
 
R
A
D
5
1
R
2
5
0
A
 
R
A
D
5
1
L
L
-
E
E
R
A
D
5
1
L
L
R
R
-
E
E
A
A
 
0
2
4
4
8
7
2
9
6
Time post-addition
of 15ng/ul doxycycline (h)
actin actin
HsRAD51Tet off
mCherry-RAD51WT
HsRAD51Tet off
mCherry-RAD51
species
A
DT40 CELL LINE GgRad51 HsRAD51Tet off mCherry-RAD51
clone 18 +/+ not present not present
Rad51-/- -/- HsRAD51Tet off not present
RAD51WT -/- HsRAD51Tet off wild-type
RAD51R250A -/- HsRAD51Tet off R250A
RAD51LL-EE -/- HsRAD51Tet off L204E, L255E
RAD51LLRR-EEAA -/- HsRAD51Tet off L204E, L255E, R247A, R250A
GENOTYPE
0 24 48 72 96
0.1
1
10
100
1000
10000
Time (h)
N
o
r
m
a
l
i
s
e
d
 
r
e
l
a
t
i
v
e
 
c
e
l
l
 
n
u
m
b
e
r
clone 18
Rad51-/- (no dox)
RAD51WT#5 (dox)
RAD51R250A#5 (dox)
RAD51LL-EE#11 (dox)
RAD51LLRR-EEAA#19 (dox)
Rad51-/- (with dox)
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(B) Cellular viability over 96h of DT40 clones stably expressing mCherry-RAD51 in a Rad51
//HsRAD51
Tet oﬀ background after addition of
doxycycline to suppress the expression of the HsRad51
Tet oﬀ transgene. Wild-type clone 18 cells, Rad51
/ cells without doxycycline treatment and
RAD51
WT cells with addition of doxycycline retain logarithmic growth. Mutant mCherry-RAD51 (RAD51
R250A, RAD51
LL-EE and RAD51
LLRR-
EEAA) cannot rescue viability. Representative clones are shown. Each point represents the mean and SEM of viable cell counts conducted
independently in triplicate. (C) A western blot indicating stable transfection of mCherry-RAD51 into Rad51
/ cells at a level comparable to
endogenous chicken Rad51 in clone 18 cells, prior to addition of doxycycline. (D) A western blot showing timedependent knock down of
HsRad51
Tet oﬀ after addition of doxycycline in a representative mCherry-RAD51
WT-expressing clone. HsRad51
Tet oﬀ expression is undetectable at
48 h. (E) A pull-down assay from DT40 whole-cell extract with indicated genotypes of mCherry-tagged RAD51 and HsRad51
Tet oﬀ with biotinylated-
BRC4 as in Figure 4. Bio-BRC4 can pull down both species in RAD51
WT cells, but can only interact with HsRad51
Tet oﬀ in mCherry-RAD51
mutants. (F) A histogram quantifying mCherry-RAD51 foci per cell in Rad51
//HsRAD51
Tet oﬀ cells expressing indicated mCherry-RAD51 species
before and after IR, 48 h after doxycycline treatment. Each bar represents the mean and SEM of data acquired in at least 500 cells by automated
microscopy. mCherry-RAD51 foci formation is apparent in RAD51
WT cells only with a signiﬁcant induction of RAD51 foci (unpaired two-tailed
t-test, P<0.0001). Cells expressing RAD51
R250A, RAD51
LL-EE, RAD51
LLRR-EEAA protein as the sole RAD51 species in a cell failed to show a
signiﬁcant induction after damage (P=0.0858, 0.7573 and 0.0715, respectively, unpaired two-tailed t-test).
Nucleic AcidsResearch, 2010,Vol. 38,No. 1 91HDR measured by sister chromatid exchange, widely used
as a sensitive and speciﬁc test for the integrity of HDR
pathways (43), at levels indistinguishable from
untransfected wild-type cells (Supplementary Figure
S3A). This conﬁrms that RAD51’s biological functions
in HDR are unaﬀected by fusion to the N-terminal
ﬂuorophore.
Three mCherry-tagged RAD51 mutants were tested.
The RAD51
R250A mutant speciﬁcally abrogates the salt
bridge between the residue R250 in RAD51, and the
E1548 residue in BRCA2 (Supplementary Figure S2,
upper right panel). The RAD51
LL-EE mutant alters the
hydrophobicity of the LFDE-binding pocket, substituting
L204 and L255 in RAD51 for glutamate residues
(Supplementary Figure S2, lower left panel). The
RAD51
LLRR-EEAA protein abrogates interactions
between four residues in RAD51 and the LFDE motif in
BRC repeats. The R250A, L204E and L255E mutations
have been described; in addition, the R247A mutation
prevents a hydrogen bond from R247 in RAD51 to the
backbone of F1546 in the BRC repeat (Supplementary
Figure S2, lower right panel).
Mutations in RAD51 that prevent its oligomerization
and/or its interaction with BRC repeats, compromise cell
viability (10). The ability of these mCherry-tagged RAD51
mutants to sustain the viability of Rad51
/ DT40 cells
was tested. Untransfected wild-type DT40 cells (clone 18),
Rad51
/ cells expressing HsRAD51
Tet oﬀ without
doxycycline treatment, and cells expressing mCherry-
RAD51
WT were viable (Figure 7B and Supplementary
Figure S3B). However, none of the three RAD51
mutants, RAD51
R250A, RAD51
LL-EE or RAD51
LLRR-
EEAA, sustained viability in the presence of doxycycline,
phenocopying the inviability of Rad51
/ cells in which
the expression of HsRAD51
Tet oﬀ has been switched oﬀ by
doxycycline treatment (28,44). This was true of multiple,
independent clones; suggesting that abrogation of the
interaction between the LFDE motif in the BRC repeats
of chicken Brca2, and its cognate binding pocket in
RAD51, ablates RAD51 function. However, the inabil-
ity of the RAD51 mutants to sustain cell viability
precludes assays for sister chromatid exchange or
genotoxin sensitivity.
To test the ability of mutant RAD51 to bind to BRC
repeats, we chose for further analysis individual clones
that expressed wild-type or mutant forms of mCherry-
RAD51 at levels comparable to that of endogenous
Rad51 in the parental DT40 (clone 18) cells (Figure 7C).
After doxycycline treatment, wild-type HsRAD51
Tet oﬀ
protein was undetectable after 48h (Figure 7D) but the
expression of wild-type or mutant forms of mCherry-
tagged RAD51 was unaﬀected. Due to the inviability of
cell lines expressing mutant RAD51 alone, lysates
prepared from untreated cells expressing mCherry-
tagged RAD51 mutants, but retaining expression of
wild-type HsRAD51
Tet oﬀ, were incubated with a
biotinylated BRC4 peptide (Bio-BRC4) bound to
streptavidin-coated magnetic beads, as in Figure 4. Bio-
BRC4 is capable of pulling-down wild-type human
RAD51 (HsRAD51
Tet oﬀ) from all lysates (Figure 7E,
left-hand panel). mCherry-RAD51
WT can also be pulled-
down by Bio-BRC4 (right-hand panel, lane 1), conﬁrming
that this interaction is unaﬀected by the ﬂuorophore tag.
However, the three mCherry-RAD51 mutants
(RAD51
R250A, RAD51
LL-EE, RAD51
LLRR-EEAA) were
defective in binding to Bio-BRC4 (left-hand panel, lanes
2–4). At high exposure, we ﬁnd that small amounts of
mCherry-RAD51
R250A can be pulled-down by Bio-
BRC4, although it is clearly not the favoured binder of
BRC4 when wild-type RAD51 (HsRAD51
Tet oﬀ) is also
present in the cell lysate. This suggests that this single
mutation, the least severe of those tested, may retain
weak BRC repeat interaction, but this is insuﬃcient to
support its function necessary for cell viability.
Besides compromising cellular viability, mutations in
RAD51 that impair its ability to interact with BRCA2
suppress its assembly in nuclear foci at sites of DNA
damage (10,11,45,46). We therefore tested the ability of
cells carrying wild-type and mutant forms of mCherry-
RAD51 to form nuclear foci after their exposure
to 3 Gy ionizing radiation (IR). These experiments
were performed 48 h after the cells were treated with
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92 Nucleic AcidsResearch, 2010,Vol. 38,No. 1doxycycline, when only the wild-type or mutant mCherry-
tagged RAD51 species are expressed (Figure 7D), and the
cells are still fully viable (Figure 7B). Whereas mCherry-
RAD51
WT forms IR-induced foci (quantitated by
automated ﬂuorescence microscopy in Figure 7F, with
representative confocal images shown in Supplementary
Figure S4), none of the three mCherry-tagged RAD51
mutants, RAD51
R250A, RAD51
LL-EE or RAD51
LLRR-
EEAA, exhibit foci formation. Taken together, these
ﬁndings provide direct evidence that the ability of
Figure 8. The LFDE binding pocket in HsRad51 is a feature of eukaryotic Rad51. A ClustalW sequence alignment is presented of HsRAD51 and
orthologues in other eukaryotes, archaea (RadA) and eubacteria (RecA) across human residues 180–284 and rendered with JalView. Blue circles
(above sequence) indicate residues within 5A ˚ of BRC4 residues L1545 and F1546 in HsRAD51 from PDB 1N0W. Residues marked with a red star
indicate residues mutated in this study (L204, R247, R250 and L255). R250A is conserved across eukaryotic Rad51 (conservatively as lysine in C.
elegans) but also present in bacterial RecA (though not the archaeal lineage, RadA).
Nucleic AcidsResearch, 2010,Vol. 38,No. 1 93RAD51 to bind the LFDE motif in the BRC repeats via
interactions mediated by the residues R247, R250, L205
and L255 is essential for its biological functions in DNA
repair. These in vivo ﬁndings conﬁrm in vitro experiments
which identify the LFDE motif as a second, previously
unrecognized tetrameric motif in the BRC repeats that
mediates structural and functional interactions with
RAD51.
DISCUSSION
In this study, we have combined structural, cell biological,
genetic and biochemical analyses to demarcate two
distinct binding motifs within the BRC repeats that
mediate functional interactions with RAD51 though cor-
responding, distinct binding pockets in RAD51. Whilst
one motif, denoted FxxA, is known to inhibit RAD51
assembly by blocking oligomerization (13), we identify a
second, denoted LFDE, which engages RAD51 at a
distinct site distant from the oligomerization interface.
We show that both motifs are required for RAD51
binding by BRC repeats. Interestingly, their co-location
within a single functional BRC repeat is necessary for
inhibitory and permissive regulation of RAD51 function;
the motifs lack such regulatory ability in isolation.
Emphasizing the mechanistic importance of these
observations, mutation of the LFDE-binding pocket in
RAD51 causes cellular lethality and a failure of RAD51
assembly into nuclear foci at sites of DNA breakage in
vivo. Thus, our ﬁndings deﬁne two motifs within the
BRC repeats whose structural and functional interaction
with RAD51 is essential for its biological function.
The evolutionary conservation of the LFDE motif in
BRC repeats from diverse organisms is striking (3). In
all eight human BRC repeats (Figure 1D) as well as in
almost all known BRC repeats from other organisms,
the initiating dihydrophobic motif ‘LF’ is conserved as
two hydrophobic residues. In particular, a hydrophobic
residue in the second position is absolutely conserved
and rare deviation only occurs if another repeat exists in
the same BRCA2 orthologue that maintain this consensus
(e.g. the ﬁfteenth repeat of Trypanosoma brucei Brca2 that
deviates from the other fourteen repeats in this respect).
We note that it is this second position in BRC4 (F1546)
that can be conservatively substituted with a tryptophan,
with retention of RAD51 binding (Figure 2B and
Figure 4A), highlighting the importance of the chemical
nature of this residue.
The fourth position of the LFDE motif, comprising an
acidic residue, is less strongly conserved in evolution.
It forms a salt bridge with R250 in RAD51 in the
BRC4-RAD51 complex (13). This residue is not always
conserved, even in BRC repeats known to be strong
RAD51 binders in vitro (e.g. human BRC3). Indeed, abro-
gation of the E1548A-R250 salt bridge by an R250A
mutation in RAD51 signiﬁcantly weakened, but did not
fully abrogate, its in vitro interaction with BRC4
(Supplementary Figure S6D), consistent with interaction
studies performed in the presence of competing wild-type
RAD51 (Figure 7D). Nevertheless, the abrogation of
this interaction with an R250A mutation in RAD51
phenocopies the cellular lethality and failure in
RAD51 focus formation that also occurs in other
RAD51 mutants, implying that even weakening of
E1548-R250 salt bridge is suﬃcient to disrupt BRC–
RAD51 interaction in vivo.
The conservation of the LFDE motif in the BRC
repeats of BRCA2 orthologues is mirrored by the con-
servation of its cognate binding-pocket in RAD51
orthologues. Interestingly, this conservation extends to
yeast Rad51 and even to archaeal RadA. Because these
organisms lack BRCA2, our ﬁndings raise the possibility
that the pocket is used for interactions with alternative
binding partners (8,47).
The conservation of RAD51 R250, which forms a salt
bridge with the E1548 residue in the LFDE motif of
BRC4, is of particular interest. R250 is strongly conserved
as R177 in E. coli RecA, providing insights into its poten-
tial role in RAD51 (Supplementary Figure S5, left panels)
(5,6). The recently reported structure of RecA assembled
on DNA substrates shows that R177 may be important
for oligomerization on both ssDNA and dsDNA, and in
interaction with the phosphate backbone of DNA (48).
However, such interactions do not appear to be essential
for RAD51 assembly. Thus, a mutant form of RAD51
carrying an R250A substitution (Supplementary
Figure S6A) showed intact interaction with both ss and
dsDNA (Supplementary Figure S6B) and was capable
of oligomerization as assessed by GST-pull down
(Supplementary Figure S6C).
In Ec RecA, R177 is capable of forming a salt bridge
with E155 of an adjacent RecA protomer in a nucleo-
protein ﬁlament (Supplementary Figure S5B and C) but
not in the absence of DNA (Supplementary Figure S5A)
(48). E155 however is not conserved in eukaryotic
RAD51. Instead, a structural alignment of the BRC4-
RAD51 complex on the core catalytic domain of RecA
protomers in oligomeric states both on and oﬀ DNA
suggests that the E1548-R250 salt bridge between BRC4
and RAD51 structurally mimics the E155-R177 contact
between protomers in a RecA ﬁlament (Supplementary
Figure S5, right panels). This is reminiscent of the struc-
tural conservation between 27-IMRL-30 at the protomer
interface in EcRecA, and the 1524-FHTA-1527 motif in
BRC4 of human BRCA2 (13). We are tempted to specu-
late that the E1548-R250 salt bridge may represent a
second example of ‘molecular mimicry’ by BRC repeats
of contacts between RecA protomers, which is used
in higher species for the regulation of RAD51 by
BRCA2 (13).
It is unclear, however, whether the R177-E155 salt
bridge between RecA promoters is structurally conserved
between protomers in RAD51 ﬁlaments, in the absence of
any high-resolution crystal structures. It is clear from
crystallographic analysis of orthologous proteins and
low-resolution electron microscopic analysis of nucleo-
protein ﬁlaments that R250 in RAD51 does localize at
an interface (22,49–52). It is conceivable that, like its bac-
terial counterpart, R250 functions in a buried salt bridge
in the human RAD51 ﬁlament as a ‘molecular clasp’
at a RAD51 interface in a nucleoprotein ﬁlament (48).
94 Nucleic AcidsResearch, 2010,Vol. 38,No. 1If correct, this salt bridge might serve a stabilizing role
in RAD51 assembly, directly or via the RAD51 ATPase
activity, that could be regulated by BRC repeats capable
of ‘mimicking’ this interaction using an LFDE interactive
mode. Thus, our ﬁndings suggest evolutionary links in the
structure of protein–protein interactions essential for the
regulation of RAD51 assembly on DNA substrates during
HDR that warrant further investigation.
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Supplementary Data are available at NAR Online.
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